Want to see HK:6185 full AI Analyst Report?
CanSino Biologics, Inc. Class H (6185) AI Stock Analysis
Top Page
CanSino Biologics, Inc. Class H
(HKEX:6185)
The score is held back primarily by weak cash conversion (negative free cash flow despite improved earnings) and bearish technical momentum (below key moving averages with negative MACD). A solid balance sheet and sharp recent revenue rebound provide some support, but the very high P/E meaningfully increases valuation risk.
CanSino Biologics, Inc. Class H (6185) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 9.03B
- Dividend Yield
- ―
- Average Volume (3M)
- 6.44M
- Price to Earnings (P/E)
- 632.6
- Beta (1Y)
- 1.29
- Revenue Growth
- 36.09%
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 1,134
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
CanSino Biologics, Inc. Class H Business Overview & Revenue Model
Company Description
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus...
How the Company Makes Money
CanSino primarily makes money by selling vaccines and vaccine-related products to customers such as public health agencies, disease control organizations, and other healthcare procurement channels, generating revenue when vaccine doses are delivered...
CanSino Biologics, Inc. Class H Financial Statement Overview
Summary
Strong TTM revenue rebound (~182%) and a return to modest net profitability, supported by a relatively solid balance sheet (debt-to-equity ~0.20). However, earnings quality is weak with negative TTM free cash flow (about -64m) despite positive net income, and profitability remains fragile/volatile with slightly negative TTM EBIT.
Income Statement
52NeutralBalance Sheet
71PositiveCash Flow
38Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.25B | 1.03B | 846.34M | 345.18M | 1.03B | 4.30B |
| Gross Profit | 899.75M | 681.82M | 601.91M | -876.02M | -186.61M | 3.00B |
| EBITDA | 43.36M | 60.98M | -163.84M | -1.65B | -1.30B | 1.87B |
| Net Income | 29.72M | 27.15M | -378.88M | -1.48B | -909.43M | 1.91B |
Balance Sheet | ||||||
| Total Assets | 6.84B | 7.18B | 7.96B | 9.32B | 11.47B | 11.87B |
| Cash, Cash Equivalents and Short-Term Investments | 1.77B | 2.65B | 3.20B | 4.12B | 5.95B | 7.78B |
| Total Debt | 929.08M | 1.29B | 2.01B | 2.70B | 2.70B | 1.37B |
| Total Liabilities | 1.84B | 2.05B | 3.05B | 4.03B | 4.22B | 3.33B |
| Stockholders Equity | 5.01B | 4.96B | 4.91B | 5.27B | 6.75B | 8.00B |
Cash Flow | ||||||
| Free Cash Flow | -63.56M | -152.83M | -626.42M | -1.53B | -2.96B | 811.42M |
| Operating Cash Flow | 95.95M | 32.49M | -168.79M | -916.25M | -1.89B | 2.01B |
| Investing Cash Flow | 949.86M | 355.36M | 3.96M | -449.65M | -1.19B | -2.53B |
| Financing Cash Flow | -533.05M | -703.03M | -334.18M | -7.58M | 854.60M | 1.56B |
CanSino Biologics, Inc. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6185, the sentiment is Negative. The current price of 25.78 is below the 20-day moving average (MA) of 31.33, below the 50-day MA of 30.21, and below the 200-day MA of 29.64, indicating a bearish trend. The MACD of -1.15 indicates Positive momentum. The RSI at 37.51 is Neutral, neither overbought nor oversold. The STOCH value of 7.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6185.
CanSino Biologics, Inc. Class H Peers Comparison
Overall Rating
HK:369274.5Outperform
HK:998956Neutral
HK:262749Neutral- HK:618545.6Neutral
HK:001345Neutral
HK:257543Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:3692 | 75Outperform | HKD 196.24B | 24.96 | 18.26% | 1.50% | 24.97% | 43.23% |
| HK:9989 | 56Neutral | HKD 14.42B | 185.14 | 1.58% | 4.22% | 3.10% | -46.64% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2627 | 49Neutral | HKD 11.54B | -37.70 | -101.49% | ― | ― | ― |
| HK:6185 | 46Neutral | HKD 13.23B | 632.61 | 0.60% | ― | 36.09% | ― |
| HK:0013 | 45Neutral | HKD 18.13B | 143.19 | 1.43% | ― | -8.55% | -96.20% |
| HK:2575 | 43Neutral | HKD 4.45B | -18.04 | -15.68% | ― | 237.19% | 61.28% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:6185 | CanSino Biologics, Inc. Class H | 25.78 | -21.42 | -45.38% | |
| HK:0013 | HUTCHMED (China) Limited | 20.78 | -2.98 | -12.54% | |
| HK:9989 | Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H | 3.94 | -1.40 | -26.20% | |
| HK:3692 | Hansoh Pharmaceutical Group Company Limited | 32.36 | -2.99 | -8.45% | |
| HK:2627 | Ab&B Bio-Tech CO., LTD. JS Class H | 29.32 | -10.52 | -26.41% | |
| HK:2575 | Xuanzhu Biopharmaceutical Co., Ltd. Class H | 8.60 | -57.75 | -87.04% |
CanSino Biologics, Inc. Class H Corporate Events
CanSino Biologics Posts Revenue Growth but Core Profit and Cash Flow Under Strain
CanSino Biologics Inc. has released its unaudited third quarterly report for the nine months ended 30 September 2026, prepared under Chinese Accounting Standards and filed as inside information in Hong Kong. The board and senior management state that...
CanSino Biologics Schedules Board Meeting to Approve Third-Quarter Results
CanSino Biologics Inc., a PRC-incorporated biopharmaceutical company listed in Hong Kong, develops and commercializes biological products and vaccines, and is overseen by a diversified board that includes executive, non-executive and independent dire...
CanSino Biologics Grants Reserved Restricted Shares Under 2025 Incentive Scheme
CanSino Biologics Inc. has approved the grant of 287,400 reserved restricted A shares under its 2025 A Share Incentive Scheme to 19 participants who meet the grant conditions, at a grant price of RMB41.20 per share, compared with a closing market pri...
CanSino Biologics Publishes Unaudited Interim Results for First Half of 2026
CanSino Biologics Inc. announced its unaudited interim results for the six months ended June 30, 2026, confirming that the figures comply with Hong Kong listing requirements for preliminary interim disclosures. The board and its audit committee have...
CanSino Biologics Advances mRNA Platform and Forms Cancer Vaccine Alliance
CanSino Biologics Inc. has highlighted the development of its mRNA technology platform, which underpins its pipeline of mRNA preventive vaccines and therapeutic biologics. The company is pushing early-stage research on mRNA vaccines for glioblastoma,...
CanSino Wins NMPA Approval for New Tetanus Vaccine, Boosting Adult Vaccine Portfolio
CanSino Biologics Inc., a Hong Kong-listed Chinese vaccine developer, is broadening its product portfolio and market reach, with a particular focus on adult immunizations in Greater China. The company leverages advanced, animal-free production techno...
CanSino’s Td5cp Booster Wins Priority Review After NDA Acceptance in China
CanSino Biologics Inc. has announced that China’s National Medical Products Administration has accepted its new drug application for the Td5cp Adolescent and Adult vaccine. The product is a tetanus, reduced diphtheria and acellular pertussis fi...
CanSino Biologics Sets Board Meeting to Approve Interim Results and Consider Dividend
CanSino Biologics Inc. has scheduled a board meeting for August 27, 2026 to review and approve the interim financial results for the six months ended June 30, 2026, along with their planned publication. The board will also consider whether to recomme...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026